1. Quantifying Antibody Persistence After a Single Dose of <scp>COVID</scp> ‐19 Vaccine Ad26. <scp>COV2</scp> .S in Humans Using a Mechanistic Modeling and Simulation Approach
- Author
-
Anna Dari, Muriel Boulton, Martine Neyens, Mathieu Le Gars, Belén Valenzuela, Georgi Shukarev, Vicky Cárdenas, Javier Ruiz‐Guiñazú, Jerald Sadoff, Richard M. W. Hoetelmans, and Juan José Pérez Ruixo
- Subjects
Pharmacology ,Pharmacology (medical) - Abstract
Understanding persistence of humoral immune responses elicited by vaccination against coronavirus disease 2019 (COVID-19) is critical for informing the duration of protection and appropriate booster timing. We developed a mechanistic model to characterize the time course of humoral immune responses in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-seronegative adults after primary vaccination with the Janssen COVID-19 vaccine, Ad26.COV2.S. The persistence of antibody responses was quantified through mechanistic modeling-based simulations. Two biomarkers of humoral immune responses were examined: SARS-CoV-2 neutralizing antibodies determined by wild-type virus neutralization assay (wtVNA) and spike protein-binding antibodies determined by indirect spike protein enzyme-linked immunosorbent assay (S-ELISA). The persistence of antibody responses was defined as the period of time during which wtVNA and S-ELISA titers remained above the lower limit of quantification. A total of 442 wtVNA and 1,185 S-ELISA titers from 82 and 220 participants, respectively, were analyzed following administration of a single dose of Ad26.COV2.S (5 × 10
- Published
- 2022
- Full Text
- View/download PDF